Key Investor Signals
Secured €560,000 in BioInnovation Institute backing
BioInnovation Institute selected EpiMass for its September 2026 cohort, providing a €560,000 convertible loan and support for scientific and business development.
Demonstrated tumor recognition in mouse tissue
Founder-led research used MALDI imaging and machine learning on 25 mouse skin-tumor sections, achieving 92.3% cross-validation accuracy in a 2024 study.
Built a laser-linked tissue-analysis prototype
Lauritz Brorsen’s 2024 PhD work produced a complete laser-assisted REIMS system. It integrated a tissue-removal laser, compact mass spectrometer and imaging stage.
Team
Lauritz Brorsen
CEO and Founder
- Worked as a postdoctoral researcher in skin cancer diagnostics at Bispebjerg Hospital and the University of Copenhagen in 2025.
- First-authored two 2024 papers on mass spectrometry and machine learning for squamous cell and basal cell skin cancers.
- Won the 2025 AI Award at Denmark’s AI and Pharmacology symposium for real-time skin cancer detection during laser surgery.
Product
EpiMass is developing a platform that combines a surgical laser, mass spectrometry and machine learning for dermatology procedures. It analyzes material released during tissue removal to guide the clinician. The system is in early development, with clinical evaluation being initiated.
Collecting surgical smoke
The platform is being developed to capture smoke and airborne particles released during laser surgery. This material provides a sample of the tissue being removed while the clinician works on the lesion.
Measuring tissue chemistry
Mass spectrometry reads the molecular composition of the captured material. The approach uses rapid evaporative ionization mass spectrometry, or REIMS, to generate chemical information from surgical tissue.
Classifying tissue during removal
Machine learning is intended to distinguish tumor from surrounding tissue using the molecular readout. The resulting feedback is designed to help clinicians decide where to continue or stop removing tissue during the procedure.
Market Overview
Skin cancer surgery sits within the market for dermatology diagnostic equipment and procedural guidance. Hospitals and specialist clinics buy tools that help characterize lesions and assess tissue during treatment. Laser removal creates a particular need for guidance because it destroys the material normally examined in the laboratory.
Dermatology equipment purchasing combines capital systems, software and service contracts. Specialist clinics and hospitals invest in better lesion assessment and margin assessment, while balancing procedure time, training and equipment cost. The broader imaging category provides commercial context for molecular surgical guidance.
The global diagnostic dermatology imaging device market was estimated at $5.4 billion in 2025.
Global diagnostic dermatology imaging device revenue is forecast to grow 9.7% annually in 2026–2033.
Skin cancer accounted for an estimated 49.0% of global dermatology imaging device revenue in 2025.
Hospitals represented an estimated 37.3% of global dermatology imaging device revenue in 2025.
Comparable Outcomes
MediMass
MediMass developed REIMS technology that analyzes molecules in surgical smoke. Its intelligent knife approach distinguished cancerous from normal tissue during cutting. Waters acquired substantially all MediMass assets in July 2014, including REIMS technology, patent applications, software, databases and technical expertise.
Interested in More Startups Like EpiMass?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.